New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies to establish themselves in refractory disease and potentially move earlier in treatment over time. New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies to establish themselves in refra...
Biopharmaceutical company Sanofi will stop a Phase 3 trial of its drug riliprubart for a rare neurological condition after an interim analysis of the study found it unlikely to provide sufficient efficacy.
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026 . Sanofi today announced that the riliprubart MOBILIZE phase 3 study (clinical study identifier: NCT06290128) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment will be stopped.
NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin's AI Scientist. Owkin and Sanofi have collaborated since 2021 through a €90 mill...
Sanofi launches 2026 global employee stock purchase plan Paris, June 4, 2026. Sanofi's global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries.